Immune monitoring using mRNA-transfected dendritic cells

Publikation: Bidrag til bog/antologi/rapport › Bidrag til bog/antologi › Forskning › fagfællebedømt

Standard

Immune monitoring using mRNA-transfected dendritic cells. / Borch, Troels Holz; Svane, Inge Marie; Met, Özcan.

Synthetic mRNA: Production, Introduction Into Cells, and Physiological Consequences. Bind 1428 Humana Press, 2016. s. 245-259 (Methods in Molecular Biology, Bind 1428).

Publikation: Bidrag til bog/antologi/rapport › Bidrag til bog/antologi › Forskning › fagfællebedømt

Harvard

Borch, TH, Svane, IM & Met, Ö 2016, Immune monitoring using mRNA-transfected dendritic cells. i Synthetic mRNA: Production, Introduction Into Cells, and Physiological Consequences. bind 1428, Humana Press, Methods in Molecular Biology, bind 1428, s. 245-259. https://doi.org/10.1007/978-1-4939-3625-0_16

APA

Borch, T. H., Svane, I. M., & Met, Ö. (2016). Immune monitoring using mRNA-transfected dendritic cells. I Synthetic mRNA: Production, Introduction Into Cells, and Physiological Consequences (Bind 1428, s. 245-259). Humana Press. Methods in Molecular Biology Bind 1428 https://doi.org/10.1007/978-1-4939-3625-0_16

Vancouver

Borch TH, Svane IM, Met Ö. Immune monitoring using mRNA-transfected dendritic cells. I Synthetic mRNA: Production, Introduction Into Cells, and Physiological Consequences. Bind 1428. Humana Press. 2016. s. 245-259. (Methods in Molecular Biology, Bind 1428). https://doi.org/10.1007/978-1-4939-3625-0_16

Author

Borch, Troels Holz ; Svane, Inge Marie ; Met, Özcan. / Immune monitoring using mRNA-transfected dendritic cells. Synthetic mRNA: Production, Introduction Into Cells, and Physiological Consequences. Bind 1428 Humana Press, 2016. s. 245-259 (Methods in Molecular Biology, Bind 1428).

Bibtex

@inbook{33174340008b4a4d991e09c807d5d930,
title = "Immune monitoring using mRNA-transfected dendritic cells",
abstract = "Dendritic cells are known to be the most potent antigen presenting cell in the immune system and are used as cellular adjuvants in therapeutic anticancer vaccines using various tumor-associated antigens or their derivatives. One way of loading antigen into the dendritic cells is by mRNA electroporation, ensuring presentation of antigen through major histocompatibility complex I and potentially activating T cells, enabling them to kill the tumor cells. Despite extensive research in the field, only one dendritic cell-based vaccine has been approved. There is therefore a great need to elucidate and understand the immunological impact of dendritic cell vaccination in order to improve clinical benefit. In this chapter, we describe a method for performing immune monitoring using peripheral blood mononuclear cells and autologous dendritic cells transfected with tumor-associated antigen-encoding mRNA.",
keywords = "Cancer immunotherapy, Dendritic cell, Electroporation, Immune monitoring, mRNA transfection, Vaccination",
author = "Borch, {Troels Holz} and Svane, {Inge Marie} and {\"O}zcan Met",
year = "2016",
doi = "10.1007/978-1-4939-3625-0_16",
language = "English",
isbn = "978-1-4939-3623-6",
volume = "1428",
series = "Methods in Molecular Biology",
publisher = "Humana Press",
pages = "245--259",
booktitle = "Synthetic mRNA",
address = "United States",

}

RIS

TY - CHAP

T1 - Immune monitoring using mRNA-transfected dendritic cells

AU - Borch, Troels Holz

AU - Svane, Inge Marie

AU - Met, Özcan

PY - 2016

Y1 - 2016

N2 - Dendritic cells are known to be the most potent antigen presenting cell in the immune system and are used as cellular adjuvants in therapeutic anticancer vaccines using various tumor-associated antigens or their derivatives. One way of loading antigen into the dendritic cells is by mRNA electroporation, ensuring presentation of antigen through major histocompatibility complex I and potentially activating T cells, enabling them to kill the tumor cells. Despite extensive research in the field, only one dendritic cell-based vaccine has been approved. There is therefore a great need to elucidate and understand the immunological impact of dendritic cell vaccination in order to improve clinical benefit. In this chapter, we describe a method for performing immune monitoring using peripheral blood mononuclear cells and autologous dendritic cells transfected with tumor-associated antigen-encoding mRNA.

AB - Dendritic cells are known to be the most potent antigen presenting cell in the immune system and are used as cellular adjuvants in therapeutic anticancer vaccines using various tumor-associated antigens or their derivatives. One way of loading antigen into the dendritic cells is by mRNA electroporation, ensuring presentation of antigen through major histocompatibility complex I and potentially activating T cells, enabling them to kill the tumor cells. Despite extensive research in the field, only one dendritic cell-based vaccine has been approved. There is therefore a great need to elucidate and understand the immunological impact of dendritic cell vaccination in order to improve clinical benefit. In this chapter, we describe a method for performing immune monitoring using peripheral blood mononuclear cells and autologous dendritic cells transfected with tumor-associated antigen-encoding mRNA.

KW - Cancer immunotherapy

KW - Dendritic cell

KW - Electroporation

KW - Immune monitoring

KW - mRNA transfection

KW - Vaccination

U2 - 10.1007/978-1-4939-3625-0_16

DO - 10.1007/978-1-4939-3625-0_16

M3 - Book chapter

C2 - 27236804

AN - SCOPUS:84988860683

SN - 978-1-4939-3623-6

VL - 1428

T3 - Methods in Molecular Biology

SP - 245

EP - 259

BT - Synthetic mRNA

PB - Humana Press

ER -

ID: 176375911